Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples